# Recent Advances in the Utilization of Dietary-Derived Exosome-like Nanoparticles in Inflammatory Bowel Diseases

## TL;DR

This paper reviews how dietary-derived exosome-like nanoparticles can help treat inflammatory bowel diseases by reducing inflammation and improving gut health.

## Contribution

The paper highlights recent advances in using plant- and animal-derived exosome-like nanoparticles for IBD treatment.

## Key findings

- Dietary-derived ELNs can modulate inflammation-related cytokines in IBD.
- ELNs help repair the intestinal barrier and regulate gut microbiota.
- Modifying ELNs and loading them with bioactive compounds enhances their therapeutic effects.

## Abstract

Inflammatory bowel disease (IBD) is a group of chronic autoimmune diseases, including Crohn’s disease and ulcerative colitis. The incidence of IBD has been increasing in newly industrialized countries, whereas current conventional therapeutic medications are ineffective and have unavoidable side effects. In recent years, exosome-like nanoparticles (ELNs) isolated from natural dietary ingredients have played a positive role in the treatment of IBD. These vesicles can exert therapeutic effects on IBD through modulating inflammation-related cytokines, repairing the intestinal barrier, and regulating the intestinal microbiota. In this study, we outline the physiological functions and applications of plant-and animal-derived of ELNs in IBD. Particular emphasis is given to the therapeutic mechanism and efficacy of these ELNs Additionally, the modification of ELNs and loading bioactive compounds in ELNs for improved effects on IBD are discussed. Finally, the prospects and challenges of the dietary-derived ELNs are proposed.